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Quality of Care Measures for Migraine: 
A Comprehensive Review
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FREDERICK FREITAG, D.O.,3 and STEPHEN SILBERSTEIN, M.D.4
ABSTRACT
Migraine headache is a highly prevalent, chronic, episodic disorder that is associated with
high direct and indirect costs. Migraine headache impacts not only patients, but also their
employers due to substantial decreases in workplace productivity. Despite the prevalence and
clinical and economic burdens of migraine, no national efforts to develop and implement
standardized measures of quality of care have been made. The objective of this study was to
collect and report on existing quality of care measures for migraine that could be suitable for
quality measurement at the health-plan level. Published literature, the Agency for Healthcare
Research and Quality’s National Quality Measure Clearinghouse, and resources available
from quality organizations (eg, the National Committee for Quality Assurance) were exam-
ined to identify existing quality indicators that can be used to assess the quality of care de-
livered to migraine sufferers at the health-plan level. Among the results of the study were
the following: Quality of care measures for migraine include patient-reported measures and
non-patient reported, diagnosis-related, prevention-related, and treatment-related indicators.
Most existing measures have been developed by the Institute for Clinical Systems Improve-
ment or summarized and reported by the RAND Corporation. Few of these measures can be
used to assess migraine quality of care at the health-plan level. In conclusion, many measures
exist, but they are not intended for use at the health-plan level. Incorporation of valid and re-
liable quality of care measures may increase the ability of migraine disease management pro-
grams to conform to clinical care guidelines. Significant effort is needed to determine what
and how to measure quality among health plans to improve the quality of care delivered to
individuals with migraine. (Disease Management 2007;10:138–146)
BACKGROUND
THOUGH EPISODIC IN NATURE, migraine is ahighly prevalent1 and chronic disorder that
is most prevalent among individuals in their
fourth decade,2,3 a time when they are highly
active in the professional arena.4 Direct and in-
direct costs associated with migraine are sub-
stantial. Estimates of direct health care costs
range from $US 1.25 billion5 to $11.1 billion.6
1Department of Health Policy, Jefferson Medical College, Philadelphia, Pennsylvania.
2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, New Jersey.
3Diamond Headache Clinic, Chicago, Illinois.
4Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
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Migraine negatively impacts employers, with
annual lost workplace productivity estimated
to be in the range of $16.2 billion5,7 to $28.7 bil-
lion in 2003 dollars.5 The annual indirect bur-
den of illness is estimated to be $2,834 per pa-
tient.8 Estimates of workplace absenteeism due
to migraine headache range from 1 to 7 days
per year,9–12 and presenteeism, which is de-
fined as being at work but less than 100% pro-
ductive, constitutes 89% of the total cost bur-
den among those with migraine.13
Despite the prevalence and substantial eco-
nomic burden of migraine, no standardized
measures of quality of care exist. The Health
Plan Employer Data and Information Set,
maintained by the National Committee for
Quality Assurance (NCQA) and widely used to
assess quality of care at the health-plan level,
does not include any headache- or migraine-re-
lated measures.14 The National Quality Forum
(NQF), which has recently merged with the Na-
tional Committee for Quality Health Care, and
the Ambulatory Care Quality Alliance (AQA)
have not focused attention on quality of care
for individuals with migraine headache.15,16 It
is not clear why these initiatives have not fo-
cused on migraine, but it may be due, in 
part, to a lack of understanding of migraine or
its underdiagnosis. The American Migraine
Prevalence and Prevention Study found that
only 56.2% of those with migraine had ever re-
ceived a medical diagnosis.2 Since many pub-
lications provide insights into the large clinical
and economic burden of the disorder,1–13,17
patients, employers, disease management
providers, and health plans alike will benefit
from a standardized set of migraine quality
measures. Indeed, employers have begun get-
ting involved in the management of migraine
in the workplace to help keep employees at
work and to help them maintain effectiveness
while working. These efforts are a means to re-
duce overall costs attributable to the disor-
der.18,19
Health plans and disease management
providers also are getting involved in migraine
care initiatives. Presently, 2 disease manage-
ment organizations have received accreditation
or certification by NCQA for migraine pro-
grams.14 Migraine disease management pro-
grams providing patient and physician educa-
tion, migraine diaries, patient feedback reports,
and access to telephonic disease management
units have demonstrated effectiveness in im-
proving migraine-specific humanistic out-
comes, measured by the Migraine Therapy
Assessment Questionnaire (MTQA) and the
Migraine Disability Assessment (MIDAS)
questionnaire.20,21 Integration of valid and re-
liable evidence- and consensus-based quality of
care measures can assist health plans and dis-
ease management providers in better evaluat-
ing interventions and edging intervention and
measurement activities closer to conformation
with standard of care guidelines. The purpose
of this review is to collect and report on exist-
ing quality of care measures for migraine that
could be suitable for quality measurement at
the health-plan level.
TRANSLATION OF CLINICAL
GUIDELINES INTO 
QUALITY INDICATORS
A major milestone in migraine care was the
establishment of the US Headache Consortium,
which is composed of 7 organizations that have
an interest in improving the quality of care for
people with migraine disorders.22 Member or-
ganizations include the American Academy of
Family Physicians, the American Academy of
Neurology, the American Headache Society,
the American College of Emergency Physi-
cians, the American College of Physicians, the
American Osteopathic Association, and the
National Headache Foundation. The Consor-
tium developed an evidence-based migraine
practice parameter and, in doing so, identified
acute and long-term treatment goals that in-
cluded reducing attack frequency and severity,
reducing disability, improving quality of life,
preventing headache, avoiding headache med-
ication escalation, and educating and enabling
patients to manage their disease.22 To achieve
these goals, the consortium developed the rec-
ommendations summarized in Table 1.
Translating the care delivered to individuals
with migraine headache into measurable indi-
cators of quality is challenging. The Institute of
Medicine defines quality as, “The degree to
which health services for individuals and pop-
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ulations increase the likelihood of desired
health outcomes and are consistent with cur-
rent professional knowledge.”23 Quality of care
can be measured along any 1 of 3 domains. This
“Quality Triad” includes structures (ie, the
“bricks and mortar” of care delivery), processes
(ie, the way care is delivered), and outcomes
(ie, the results of care).24 An example of a pro-
cess measure is using a beta-blocker after
myocardial infarction in patients without con-
traindications to such therapy. Such an indica-
tor of quality is supported by substantial clin-
ical research and is now included in various
quality measurement sets. More recently, at-
tention has been given to the use of outcome
measures as the basis for quality measurement
and quality improvement.25 Outcome mea-
sures can be subdivided into clinical, human-
istic, and economic measures. The measures se-
lected should be professionally developed,
with agreed-upon standards of care, and, most
important, the measures must be interpretable
and actionable.
METHODS
To develop a migraine quality measurement
set that could be used at the health-plan level,
we conducted a resource review including pub-
lished peer-reviewed literature, the Agency for
Healthcare Research and Quality’s National
Quality Measure Clearinghouse, and resources
available from quality organizations such as
NCQA, NQF, and AQA. We grouped the iden-
tified measures as either (1) patient-reported or
(2) non-patient-reported. Within the non-patient-
reported measures, there are (a) diagnosis-re-
lated, (b) treatment-related, and (c) prevention-
related measures. This scheme is a standard
clinical approach and is similar to the structure
of the US Headache Consortium guidelines.22
RESULTS
Patient-reported measures
Because of the subjective nature of migraine
headaches, many measurement techniques ex-
ist that rely on patient-reported information.
We briefly discuss each of these instruments
below.
24-hour migraine quality of life questionnaire.
The 24-Hour Migraine Quality of Life Ques-
tionnaire (24-Hr-MQOLQ)26,27 is designed to
assess the health of specific populations at a
specific point in time. It is a 15-item, self-ad-
ministered questionnaire aimed at assessing
migraine sufferers’ quality of life within 24
hours of taking migraine medication and
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TABLE 1. US HEADACHE CONSORTIUM GOALS OF MIGRAINE TREATMENT AND PREVENTION*
• Educate migraine sufferers about their condition and its treatment, and encourage them to participate in
their own management.
• Use migraine-specific agents (ie, triptans, dihydroergotamine, ergotamine) for patients with more severe
migraine and for those whose headaches are known to respond poorly to nonsteroidal anti-inflammatory
drugs, or NSAID, or combinations such as aspirin plus acetaminophen plus caffeine.
• Select a non-oral route of administration for patients whose migraines present early with nausea or
vomiting as a significant component of the symptom complex.
• Consider a self-administered rescue medication for patients with severe migraines that do not respond well
to (or fail) other treatments.
• Guard against medication-overuse headache. (“Rebound headache” or “drug-induced headache” are
sometimes used interchangeably with “medication over-use headache.”)
• Preventive therapy in appropriately guided clinical presentations, including:
 Headache frequency more than 2 days per week (or 8 days/month).
 Use of acute medications, successfully or unsuccessfully, more than 2 days per week.
 Headache attacks that remain disabling despite aggressive acute intervention, as documented by lifestyle
interference, ratings on disability scales, or use of rescue medications more than once a month.
 Presence of prolonged aura (1 hour), complex aura (basilar or hemiplegic), or migraine-induced stroke.
 Contraindications to, failure of, overuse of, or adverse events with acute therapies.
 Patient desire to reduce frequency of acute attacks.
*Adapted from the US Headache Consortium Guidelines22
within the first 24 hours of a migraine attack.
Items cover a number of domains including
work, social, energy, vitality, feelings, con-
cerns, and migraine symptoms.
Migraine-specific quality of life. The Migraine-
Specific Quality of Life (MSQOL)28 is a 25-item
self-administered instrument developed to
measure the long-term effects of migraine and
migraine treatment on quality of life. Items are
summed to provide an overall score and 3 sub-
scores measuring physical, emotional, and so-
cial domains. A total MSQOL score also can be
calculated.
Migraine-specific quality of life questionnaire,
version 2.1. The Migraine-Specific Quality of
Life Questionnaire, version 2.1 (MSQ v.2.1)29,30
is a 14-item, self-administered instrument cov-
ering areas of specific concern to persons with
migraine. Specifically, it addresses factors of
role restrictive, role preventive, and emotional
function. It was developed from the MSQ v.1.0
and subsequently shortened for easier admin-
istration; its content was improved by reword-
ing certain items for greater clarification. The
MSQ v.2.1 is intended to respond to a perceived
need to develop a health status measure that
would adequately focus on the physical and
emotional limitations that are typically associ-
ated with migraine headaches.
Migraine disability assessment scale. Migraine
Disability Assessment Scale (MIDAS)31,32 is a
questionnaire that measures migraine-related
disability based on the number of days of lost
and limited activity due to migraine. Activities
are classified into 3 areas, which include (1)
paid work and education (school/college); (2)
household work (unpaid work such as house-
work, shopping, and caring for children and
others); and (3) family, social, and leisure ac-
tivities. Patients with migraine count the num-
ber of days on which they missed out on ac-
tivities because of migraine in the previous 3
months. They also count the number of days
on which their productivity was, at most, half
of normal in paid and household work. The
overall MIDAS score is calculated by summing
the answers to these 5 questions, and is scored
in number of days.
Headache disability inventory. The Headache
Disability Inventory (HDI)33,34 is a 25-item in-
strument developed to quantify the impact of
headache, though not specifically migraine,
and its treatment on daily living. Items are di-
chotomized and answered with either “yes” (4
points), “sometimes” (2 points), or “no” (0
points). Based on a scale of 0–100, the scores in-
dicate patients’ self-perceived headache dis-
ability. These measures assist the physician in
determining the medical relevance of patients’
headaches.
Headache impact questionnaire. The Headache
Impact Questionnaire (HImQ)35,36 is a 16-item,
self-administered questionnaire used to mea-
sure pain and activity limitations from head-
ache, though not specifically migraine, over a
3-month recall period. This instrument was de-
veloped to capture information about pain and
headache-related disability to help doctors and
patients evaluate the impact of headache on the
individual’s daily life. Headache-related dis-
ability is expressed as hours or days of lost pro-
ductivity and functioning.
Headache impact test. The Headache Impact
Test (HIT)37–39 is a tool that measures the im-
pact headaches, though not specifically mi-
graine, have on a person’s ability to function
on the job, at home, at school, and in social sit-
uations. The HIT builds on previous work by
pooling items from 4 existing measurement in-
struments: MSQ, HDI, HIMQ, and MIDAS.
Items cover a broader spectrum of health out-
comes than any of the original scales, ranging
from pain to emotional distress. Two versions
exist, the computer adaptive testing (CAT)-HIT
and the HIT-6. The CAT-HIT is administered
over the Internet, whereas the HIT-6 is a static,
short-form version of the HIT for paper-and-
pencil administration.
Migraine therapy assessment questionnaire. The
Migraine Therapy Assessment Questionnaire
(MTAQ)40 is a 9-item, patient-completed ques-
tionnaire that was developed to identify indi-
viduals whose migraine management may be
suboptimal. MTAQ was created in an effort to
identify barriers to optimal migraine manage-
ment and improve patient outcomes.
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Migraine assessment of current therapy. The
Migraine Assessment of Current Therapy (Mi-
graine-ACT)41 is a 4-item assessment tool in-
tended to evaluate how well a recently pre-
scribed acute medication is working, and to
identify patients who require a change in acute
treatment. The questions were formulated in 4
domains including headache impact, global as-
sessment of relief, consistency of response, and
emotional response.
In addition to patient self-report survey in-
struments, the Institute for Clinical Systems
Improvement (ICSI) suggests some provider-
level humanistic indicators of patient func-
tional status including percentage of days per
month with migraine for migraine sufferers;
hours (days) per month lost due to migraine
for migraine sufferers; rate of emergency de-
partment usage by migraine sufferers for mi-
graine; and percentage of migraine sufferers
with a headache calendar or diary.42
ICSI is an independent, nonprofit organiza-
tion that facilitates health care quality improve-
ment initiatives among providers in Minnesota
and surrounding areas. The organization devel-
ops diagnosis and treatment algorithms for var-
ious conditions, including headache, and estab-
lishes priority aims and suggested measures to
improve the quality of care for these conditions.
The seventh edition of the diagnosis and treat-
ment of headache guidelines, released in Janu-
ary of 2006, includes indicators (with measure-
ment specifications) of quality for headache at
the provider level based on chart review. While
these measures may be important to consider in
developing a migraine-specific quality measure
set, implementing such measures may be diffi-
cult at the health-plan level because chart review
may not be feasible for health plans. Further-
more, these types of measures may be sub-
optimal for disease management programs op-
erating in collaboration with health plans
because it would require program providers to
cull additional data not available through the
health plan, thereby increasing required re-
sources and costs.
NON-PATIENT-REPORTED MEASURES
In 2003, McGlynn and colleagues at the RAND
Cooperation published a landmark study which
sought to quantify the extent to which quality
health care was delivered in the United States.43
Among the 439 performance indicators included
in the study, 21 were specific to headache (not
specifically migraine). These indicators were de-
rived from a literature review conducted by re-
searchers at the RAND Corporation.44,45 The re-
searchers conducted a MEDLINE search of
English language articles between 1990 and 1997,
using the keywords headache, diagnosis, and
treatment. Of the 14 articles identified, 9 were re-
view articles and 5 were observational studies.
Each of the indicators that were collected was
categorized as either a diagnosis indicator or a
treatment indicator.
In the aforementioned article, McGlynn and
colleagues classified all the measures in the
comprehensive collection on a number of do-
mains, including unit (ie, patient, dyad,
episode); type (ie, preventive, acute, chronic);
function (ie, screening, diagnosis, treatment,
follow-up); modality (ie, history, physical ex-
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TABLE 2. DIAGNOSIS-RELATED MIGRAINE QUALITY OF CARE INDICATORS*
• Patients with new onset headache should have an examination evaluating the cranial nerves.
• Patients with new onset headache should have an examination evaluating the fundi.
• Patients with new onset headache should have an examination evaluating deep tendon reflexes.
• Patients with new onset headache should have an examination evaluating their blood pressure.
• CT or MRI scanning is indicated in patients with new onset headache and an abnormal neurological
examination.
• CT or MRI scanning is indicated in patients with new onset headache and a severe headache.
• Percentage of headache sufferers diagnosed with migraine.
• Percentage of headache sufferers diagnosed with tension-type headache.
• Percentage of headache sufferers diagnosed with cluster headaches.
• Percentage of headache sufferers diagnosed with sinus headaches.
CT, Computed tomography; MRI, Magnetic resonance imaging.
*Adapted from references 42, 44, 45.
amination, counseling/education, encounter or
other intervention, medication, laboratory/
radiology, immunization); problem (ie, un-
deruse, overuse); and level of evidence (ie,
randomized trial, nonrandomized controlled
study [eg, case control], observational study/
expert opinion).43 The rate of performance for
each indicator was calculated to estimate the
percentage of recommended care received by
study participants. Mean scores for headache
quality indicators ranged from 8.21% (patients
with new-onset headache should be asked
about family history of headache) to 100%
(sumatriptan and ergotamine should not be
given to patients with a history of ischemic
heart disease or angina). In other words, on av-
erage, patients received recommended care be-
tween 8.21% to 100% of the time based on vari-
ous indicators. Overall, recommended care for
headache was received 45.2% of the time.43
Clearly, performance varied widely across dif-
ferent indicators of care. Of the 21 headache qual-
ity measures included in this study, the indica-
tors that best lend themselves to measures rather
than just guidelines are included in Tables 2 and
3. Because these indicators are for headache, they
may not apply to migraine specifically.
All of the non-patient-reported measures 
are classified as either diagnosis-related42,44,45
(Table 2) or treatment- and prevention-
related42,44–48 (Tables 3 and 4). The RAND 
authors assert that screening for headaches is
not recommended because the problem is
symptomatic.44,45 However, Lipton and col-
leagues developed the ID Migraine, a 3-item
questionnaire used to screen for and diagnose
migraine in the physician’s office.50 Cady and
others have developed similar questionnaires.51
The ICSI guidelines suggest that several mea-
sures could be used to increase the accurate 
diagnosis and subsequent treatment of head-
aches. In addition to the treatment- and pre-
vention-related measures set forth by the
RAND authors, ICSI suggests several provider-
level treatment and prevention-related quality
measures that are intended to increase the rate
of treatment plans for mild, moderate, and 
severe headaches for migraine sufferers and to
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TABLE 3. TREATMENT-RELATED AND PREVENTION-RELATED MIGRAINE QUALITY OF CARE INDICATORS*
• Patients with acute mild migraine or tension headache should have tried aspirin, acetaminophen, or other
nonsteroidal anti-inflammatory agents before being offered any other medication.
• For patients with acute moderate or severe migraine headache, one of the following should have been tried
before any other agent is offered: ketorolac, sumatriptan, diydroergotamine, ergotamine, chlorpromazine, or
metoclopramide. According to the DISC study by Lipton, the severity of migraine headache would dictate
the first medication that someone takes, called the stratified approach.
• Recurrent moderate or severe tension headaches should be treated with a trial of tricyclic antidepressant
agents if there are no medical contraindications to their use.
• Patients experiencing more than 2 moderate-to-severe migraine headaches per month, should be offfered
prophylactic treatment with one of the following: beta-blockers, calcium channel blockers, topiramate,
tricyclic antidepressants, naproxen, aspirin, fluoxetine, valproate, or cyproheptadine. Angiotensin II receptor
blockers have also demonstrated efficacy in the prevention of migraines. (Table 4 summarizes the level of
evidence of pharmacological agents for migraine prophylaxis according to the US Headache Consortium
Guidelines for Migraine Prophylaxis.)
• Sumatriptan and ergotamine should not be administered concurrently.
• Opioid agonists and barbiturates should not be first-line therapy for migraine or tension headaches, except
in patients where more specific agents are medically contraindicated.
• Sumatriptan and ergotamine should not be given to patients with a history of uncontrolled hypertension,
ischemic heart disease, or angina.
• Percentage of migraine sufferers with treatment plans for mild, moderate, and severe headaches.
• Percentage of migraine sufferers with a treatment plan who adhere to that plan for mild, moderate, and
severe headaches.
• Number of prescriptions filled with narcotics or barbiturates for the treatment of migraine.
• Percentage of migraine sufferers with a prescription of narcotics or barbiturates for the treatment of
migraine.
• Percentage of migraine sufferers with documented education.
• Percentage of migraine sufferers prescribed appropriate prophylactic treatment based on headache type.
• Percentage of migraine sufferers prescribed appropriate acute treatment based on level of severity.
• Percentage of migraine sufferers prescribed appropriate prophylactic treatment based on level of severity.
*Adapted from references 42, 44–48.
reduce the use of narcotics and barbiturates for
treatment (Table 3).
DISCUSSION
Few migraine care quality measures exist, and
those that are available are not easily imple-
mented at the health-plan level. The RAND Cor-
poration collected exisiting quality indicators
and ICSI has developed provider-level quality
measures. RAND researchers conducted a liter-
ature review and sought expert opinion during
the development of a comprehensive measure-
ment set for headache, which was subsequently
used to study, as part of a much larger compila-
tion of quality measures, the quality of care de-
livered to adults in the United States. Aside from
these, few indicators exist. Most RAND study in-
dicators and the suggested ICSI measures were
intended for provider-level quality assessment
and require chart review. They are not based on
administrative data such as claims. Mandating a
health-plan quality measure based on chart re-
view creates a significant burden. An alternative
approach is to include patient self-reported mea-
sures. However, these focus mainly on symp-
toms and impact on humanistic outcomes (eg,
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TABLE 4. US HEADACHE CONSORTIUM GUIDELINES FOR MIGRAINE PROPHYLAXIS*
Group 1 • Amitriptyline
• Divalproex sodium
Medium-to-high efficacy, good strength • Timolol
of evidence, mild-to-moderate side • Propranolol
effects • Topiramate
Group 2 • Aspirin
• Atenolol
Lower efficacy, limited strength of • Fenoprofen
evidence, mild-to-moderate side effects • Flurbiprofen
• Fluoxetine
• Gabapentin
• Ketoprofen
• Metoprolol
• Nadolol
• Naproxen
• Nimodipine
• Verapamil
• Botulinum toxin type A
Group 3 • Cyproheptadine
• Antidepressants such as nortriptyline,
No scientific evidence of efficacy, but • paroxetine, venlafaxine, doxepin,
clinically efficacious based on • sertraline, and phenelzine
consensus of experience • Methylergonovine
a. Low-to-moderate adverse
a. events
b. Frequent or severe adverse
a. events (or safety concerns);
a. complex management issues
Group 4 • Methysergide
Medium-to-high efficacy, good strength
of evidence, but side effect concerns
Group 5 • Acebutolol
• Pindolol
Evidence indicating no efficacy over • Carbamazepine
placebo • Nicardipine
• Nifedipine
• Indomethacin
*Adapted from portions of the US Headache Consortium Guidelines for Migraine. Prophylaxis.22,49
functionality and quality of life) and do not usu-
ally lend themselves to health-plan level quality
assessment. Surveys also may be more difficult
for a health plan to implement than measures
based on existing health-plan claims data.
Existing migraine disease management mod-
els have relied on humanistic outcomes to as-
sess their effectiveness. While patient-reported
outcomes are important, administation of sur-
veys may not be feasible for program providers
and the outcomes assessment may not be rele-
vant to the health-plan customers. A quality
measurement set needs to be based on agreed-
upon standards of care and expected outcomes.
Cost, feasibility, and relevance of the measures
to health care purchasers must be considered.
A plan-level migraine quality measure set is
needed and would benefit disease manage-
ment providers offering migraine programs.
While a good range of measures exist, signifi-
cant effort is needed to determine what and
how to measure quality at the plan level.
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